BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34565290)

  • 1. Artificial intelligence-based measurements of PET/CT imaging biomarkers are associated with disease-specific survival of high-risk prostate cancer patients.
    Polymeri E; Kjölhede H; Enqvist O; Ulén J; Poulsen MH; Simonsen JA; Borrelli P; Trägårdh E; Johnsson ÅA; Høilund-Carlsen PF; Edenbrandt L
    Scand J Urol; 2021 Dec; 55(6):427-433. PubMed ID: 34565290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival.
    Polymeri E; Sadik M; Kaboteh R; Borrelli P; Enqvist O; Ulén J; Ohlsson M; Trägårdh E; Poulsen MH; Simonsen JA; Hoilund-Carlsen PF; Johnsson ÅA; Edenbrandt L
    Clin Physiol Funct Imaging; 2020 Mar; 40(2):106-113. PubMed ID: 31794112
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant lipogenesis defined by
    Regula N; Häggman M; Johansson S; Sörensen J
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2131-2138. PubMed ID: 27392615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of radiomic analysis of [
    Marturano F; Guglielmo P; Bettinelli A; Zattoni F; Novara G; Zorz A; Sepulcri M; Gregianin M; Paiusco M; Evangelista L
    Eur Radiol; 2023 Oct; 33(10):7199-7208. PubMed ID: 37079030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence-based versus manual assessment of prostate cancer in the prostate gland: a method comparison study.
    Mortensen MA; Borrelli P; Poulsen MH; Gerke O; Enqvist O; Ulén J; Trägårdh E; Constantinescu C; Edenbrandt L; Lund L; Høilund-Carlsen PF
    Clin Physiol Funct Imaging; 2019 Nov; 39(6):399-406. PubMed ID: 31436365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
    Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
    Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
    Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
    Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Domachevsky L; Goldberg N; Bernstine H; Nidam M; Groshar D
    Eur Radiol; 2018 Dec; 28(12):5275-5283. PubMed ID: 29846803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations of
    Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
    Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLUT1 expression in high-risk prostate cancer: correlation with
    Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.